Drugs / INCA32459
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05577182 | Jan 2023 → Oct 2025 | cancer | Incyte Corporation | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INCA32459 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05577182 ↗ |
| Route | Intravenous | “INCA32459 will be administered at a protocol defined starting regimen intravenously.” NCT05577182 ↗ |